MedTrace Logo

A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum

NCT03077750 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2018-10-11

No results posted yet for this study

Summary

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase II Study to Evaluate the Efficacy, Tolerability, and Safety of Topical VBP-245 in Pediatric Subjects for the Treatment of Molluscum Contagiosum (VBP-245-MCV).

Conditions

  • Molluscum Contagiosum

Interventions

DRUG

VBP-245 Topical Gel

Topical application BID

DRUG

Vehicle

Vehicle Control With No Active Pharmaceutical Ingredients

Sponsors & Collaborators

  • Veloce BioPharma LLC

    lead INDUSTRY

Principal Investigators

  • Jayashri Krishnan, PhD · JSS Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-27
Primary Completion
2018-03-30
Completion
2018-04-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03077750 on ClinicalTrials.gov